Tectonic Therapeutic, Inc.
No enriched coverage for $TECX in the last 7 days.
Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.
Analysts reiterated Buy ratings on Amgen (AMGN), Tectonic Therapeutic (TECX), and Revolution Medicines (RVMD). Amgen has a $394.73 avg. price target, Tectonic $79.50, and Revolution $241.70. Analysts cited in reports include Matt Phipps, Uy Ear, and Laura Prendergast.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-
Recent TECX coverage spans financial news, technology and earnings.
In the last 30 days, TECX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2K). The most active reporter was McNamara Peter, Chief Scientific Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive trial progress may lift the stock; short interest remains high, so upside could be limited by skepticism.
Possible price appreciation if market follows new target.
Near-term catalyst path is clearer: TX2100 Phase 1a topline by end of Q3 2026, and TX45 Phase 2 topline early Q1 2027, supported by an IDMC continuation decision.
The catalyst is timeline-based (near-complete enrollment and upcoming topline), which can sustain speculative positioning.
Enrollment completion de-risks trial execution and sets a clear catalyst window for TX45 topline results.
AlphAI scores every news story that mentions TECX with an AI model for sentiment and relevance, and aggregates insider trades from Tectonic Therapeutic, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.
2 min readAnalysts reiterated Buy ratings on Amgen (AMGN), Tectonic Therapeutic (TECX), and Revolution Medicines (RVMD). Amgen has a $394.73 avg. price target, Tectonic $79.50, and Revolution $241.70. Analysts cited in reports include Matt Phipps, Uy Ear, and Laura Prendergast.
2 min readTectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-
5 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readTectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.
4 min readTectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001681087 0001681087 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2
3 min readWATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( ...
2 min readWATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. TECX ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( GPCRs ) , today ...
2 min readWATERTOWN, Mass., May 17, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection ...
2 min readData confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ( "PH-HFpEF" )
2 min read
